- Obtaining an accurate diagnosis and updated clinical prognostic indices in FL
- Selection of frontline management approaches for newly diagnosed FL
- Does the patient need treatment?
- Frontline anti-CD20 monoclonal antibody–based treatment strategies
- Antibody monotherapy
- Combination immunotherapy
- Future directions in the first-line treatment of FL
Christopher R. Flowers, MD, MS
Director, Lymphoma Program
Bone Marrow and Stem Cell Transplantation
Department of Hematology and Oncology
The goal of this activity is to improve participants’ competence in applying the latest practice-changing data in the clinical management of patients with follicular lymphoma.
This program is intended for physicians and other healthcare providers who care for patients with follicular lymphoma.
- Apply emerging clinical trial findings when formulating frontline treatment recommendations for patients with follicular lymphoma
- Integrate patient-related and disease-related characteristics, patient preferences and goals along with the available clinical evidence to individualize frontline therapy for patients with follicular lymphoma
- Refer appropriate patients with follicular lymphoma to ongoing clinical trials of investigational frontline agents and approaches
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.